Amgen Inc. $AMGN Stock Holdings Lessened by Drucker Wealth 3.0 LLC

Drucker Wealth 3.0 LLC cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 33.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 4,373 shares of the medical research company’s stock after selling 2,160 shares during the period. Drucker Wealth 3.0 LLC’s holdings in Amgen were worth $1,539,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Norges Bank bought a new position in Amgen during the 4th quarter worth $2,164,162,000. Capital World Investors grew its holdings in Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after buying an additional 4,302,237 shares in the last quarter. State Street Corp increased its position in Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after acquiring an additional 1,287,310 shares during the period. Geode Capital Management LLC raised its stake in Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after acquiring an additional 1,035,779 shares in the last quarter. Finally, Amundi raised its stake in Amgen by 41.1% during the 4th quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock valued at $1,111,854,000 after acquiring an additional 988,856 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $360.55 on Tuesday. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $391.29. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The company has a 50-day moving average of $340.92 and a 200-day moving average of $346.71. The firm has a market cap of $194.59 billion, a price-to-earnings ratio of 25.09, a price-to-earnings-growth ratio of 3.60 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.85% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. The Goldman Sachs Group set a $389.00 price target on Amgen in a report on Friday, June 5th. Erste Group Bank reiterated a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Truist Financial raised their price objective on shares of Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research note on Friday, May 1st. Jefferies Financial Group began coverage on Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price for the company. Finally, Argus decreased their price target on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus target price of $354.42.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.